Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/15/25 | AbbVie (ABBV) | Elahere for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
3/12/25 | GSK (GSK) | VH109 for HIV / AIDS Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
3/11/25 | Arvinas (ARVN) | Vepdegestrant for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
3/10/25 | Novo Nordisk (NVO) | CagriSema for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
3/10/25 | Johnson & Johnson (JNJ) | Icotrokinra for Ulcerative Colitis (UC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
12/31/2024 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
02/12/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
02/27/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
03/05/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
03/12/2025 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |